Caliciviridae infectious disease
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Virus diseases caused by caliciviridae. They include hepatitis E; vesicular exanthema of swine; acute respiratory infections in felines, rabbit hemorrhagic disease, and some cases of gastroenteritis in humans.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Caliciviridae infectious disease
- Therapeutic area
- Infectious Disease
- Caliciviridae infectious disease
- Caliciviridae infection
- Calicivirus infection
- Calicivirus infections
- infection, Caliciviridae
- infection, Calicivirus
- infections, Caliciviridae
- infections, Calicivirus
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Unknown
- MONDO ID
- MONDO:0005687
- Parent condition
- MONDO:0100329
Related records
Broader conditions (7)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Primary viral infectious disease
- Viral infectious disease
Narrower conditions (1)
Trials (17)
- A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine
- A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers
- A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
- A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants
- A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
- Admission Pattern Among Children With Gastro-intestinal Infections Before and During the Covid-19 Pandemic
- Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)
- Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)
- Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model
- Human Breastmilk in Young Children With Norovirus Infection of the Gut
- Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines
- Norovirus Challenge Study
- Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine
- Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
- Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines
- Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children